| Trial ID: | L0288 |
| Source ID: | NCT04874233
|
| Associated Drug: |
HU6
|
| Title: |
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: HU6|Drug: Placebo
|
| Outcome Measures: |
Assess the dose relationship of PK Parameter Cmax
|
| Sponsor/Collaborators: |
Rivus Pharmaceuticals, Inc.
|
| Gender: |
All
|
| Age: |
28 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
80
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
April 19, 2021
|
| Completion Date: |
December 15, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 2, 2022
|
| Locations: |
Prism Clinical Research, Minneapolis, Minnesota, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04874233
|
